ATE315033T1 - Subtituierte isoxazole derivate als estrogen rezeptor modulatore - Google Patents

Subtituierte isoxazole derivate als estrogen rezeptor modulatore

Info

Publication number
ATE315033T1
ATE315033T1 AT99940916T AT99940916T ATE315033T1 AT E315033 T1 ATE315033 T1 AT E315033T1 AT 99940916 T AT99940916 T AT 99940916T AT 99940916 T AT99940916 T AT 99940916T AT E315033 T1 ATE315033 T1 AT E315033T1
Authority
AT
Austria
Prior art keywords
estrogen receptor
subtituted
receptor modulators
isoxazole derivatives
compositions
Prior art date
Application number
AT99940916T
Other languages
English (en)
Inventor
Verena D Huebner
Xiaodong Lin
Ian James
Liya Chen
Manoj Desai
Jennifer C Moore
Beata Krywult
Thayalan Navaratnam
Rajinder Singh
Rob Trainor
Liang Wang
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE315033T1 publication Critical patent/ATE315033T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT99940916T 1998-08-07 1999-08-06 Subtituierte isoxazole derivate als estrogen rezeptor modulatore ATE315033T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9577398P 1998-08-07 1998-08-07

Publications (1)

Publication Number Publication Date
ATE315033T1 true ATE315033T1 (de) 2006-02-15

Family

ID=22253531

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99940916T ATE315033T1 (de) 1998-08-07 1999-08-06 Subtituierte isoxazole derivate als estrogen rezeptor modulatore

Country Status (8)

Country Link
US (4) US6262098B1 (de)
EP (1) EP1102755B1 (de)
JP (1) JP2002522425A (de)
AT (1) ATE315033T1 (de)
AU (1) AU5467699A (de)
DE (1) DE69929345T2 (de)
ES (1) ES2255294T3 (de)
WO (1) WO2000008001A1 (de)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410043B1 (en) 1998-05-07 2002-06-25 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6632447B1 (en) 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
ATE315033T1 (de) * 1998-08-07 2006-02-15 Chiron Corp Subtituierte isoxazole derivate als estrogen rezeptor modulatore
DE10039199A1 (de) * 2000-08-10 2002-02-21 Schering Ag Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen
JP2002069061A (ja) * 2000-08-30 2002-03-08 Canon Inc オキサゾール化合物及びそれを用いた有機発光素子
US7022725B2 (en) 2000-11-17 2006-04-04 Takeda Pharmaceutical Company Limited Isoxazole derivatives
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
IL156445A0 (en) 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
KR20070120617A (ko) 2001-01-26 2007-12-24 쉐링 코포레이션 치환된 아제티딘온 화합물을 포함하는 약제학적 조성물
DE60131967D1 (de) * 2001-08-13 2008-01-31 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
EP1429756B1 (de) 2001-09-21 2006-11-22 Schering Corporation Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US20040044226A1 (en) * 2001-10-15 2004-03-04 Dininno Frank P. Estrogen receptor modulators
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
US20040096510A1 (en) * 2001-11-29 2004-05-20 Steiner Mitchell S. Prevention and treatment of androgen-deprivation induced osteoporosis
US7524866B2 (en) * 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
MXPA04005112A (es) * 2001-11-29 2005-04-29 Gtx Inc Prevencion y tratamiento de osteoporosis inducida por privacion de androgeno.
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20050080143A1 (en) * 2001-11-29 2005-04-14 Steiner Mitchell S. Treatment of androgen-deprivation induced osteoporosis
US20040213841A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S Methods for treating hot flashes and gynecomastia
RU2004125594A (ru) * 2002-01-22 2005-03-10 Акцо Нобель Н.В. (NL) Применение тиболона при лечение симптомов, связанных с введением лекарств, препятствующих синтезу эндогенного эстрогена
CA2504916A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
JP2006515838A (ja) * 2002-11-22 2006-06-08 スミスクライン ビーチャム コーポレーション ファルネソイドx受容体アゴニスト
US7332525B2 (en) 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
KR101166749B1 (ko) 2003-02-11 2012-07-27 베르날리스(캠브리지)리미티드 열쇼크 단백질 저해제로서의 이소옥사졸 화합물
WO2004081002A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
DE602004018617D1 (de) 2003-03-07 2009-02-05 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
WO2004081004A1 (en) 2003-03-07 2004-09-23 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US20070161698A1 (en) * 2003-05-30 2007-07-12 Microbia, Inc. Modulators of CRTH2 Activity
US7205329B2 (en) * 2003-05-30 2007-04-17 Microbia, Inc. Modulators of CRTH2 activity
JP2007527397A (ja) * 2003-07-01 2007-09-27 マイクロバイア インコーポレイテッド Cox−2及びfaah阻害剤
US20070293542A1 (en) * 2003-10-16 2007-12-20 Cali Brian M Selective Cox-2 Inhibitors
US8157788B2 (en) * 2003-11-06 2012-04-17 Paolo L. Manfredi Multi-site drug delivery platform
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US20050234030A1 (en) * 2004-04-20 2005-10-20 Wilmin Bartolini Modulators of CRTH2, COX-2 and FAAH
US20050234244A1 (en) * 2004-04-20 2005-10-20 Wilmin Bartolini Synthesis of COX-2 and FAAH inhibitors
CA2564429A1 (en) * 2004-05-14 2005-12-01 Irm Llc Compounds and compositions as ppar modulators
WO2006042172A2 (en) * 2004-10-09 2006-04-20 The Regents Of The University Of Michigan Gender differences in experimental aortic aneurysm formation
JP2008515992A (ja) 2004-10-13 2008-05-15 ピーティーシー セラピューティクス,インコーポレーテッド 体細胞変異に起因する疾患の阻止/治療用医薬を製造するための規定化合物の使用
WO2007037782A2 (en) * 2005-02-08 2007-04-05 The University Of North Carolina At Chapel Hill Method for treating prostate conditions
US8546451B2 (en) 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
CA2824517A1 (en) * 2005-11-28 2007-05-31 Gtx, Inc. Nuclear receptor binding agents
NL2000351C2 (nl) * 2005-12-22 2007-09-11 Pfizer Prod Inc Estrogeen-modulatoren.
US8524663B2 (en) 2006-03-03 2013-09-03 New York University Method for site-specific polyvalent display on polymers
EP2051977A2 (de) * 2006-07-20 2009-04-29 Amgen Inc. SUBSTITUIERTE AROMATISCHE AZOL-HETEROCYCLEN ALS LLbeta-HSD-1-HEMMER
DE102007040243A1 (de) * 2007-08-25 2009-02-26 Universität des Saarlandes 17Beta-Hydroxysteriod-Dehydrogenase Typ1 Inhibitoren zur Behandlung hormonabhängiger Erkrankungen
MX2010004195A (es) 2007-10-16 2010-06-02 Repros Therapeutics Inc Trans-clomifeno para el sindrome metabolico.
FI20070897A0 (fi) * 2007-11-23 2007-11-23 Juha Pulkkinen Uudet estrogeeniaktiivisuutta omaavat 4,5-dihydroisoksatsolit
US7943619B2 (en) * 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
US7618973B2 (en) * 2007-12-04 2009-11-17 Hoffmann-La Roche Inc. Isoxazolo-pyrazine derivatives
JP5301557B2 (ja) 2007-12-04 2013-09-25 エフ.ホフマン−ラ ロシュ アーゲー イソオキサゾロ−ピリジン誘導体
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
RU2412174C1 (ru) * 2009-06-19 2011-02-20 Государственное образовательное учреждение высшего профессионального образования "Астраханский государственный университет" (АГУ) 3-замещенные 4,4(5н)-дикарбонитрил-5-фенилизоксазолины, обладающие противогрибковой активностью
WO2011009484A1 (en) * 2009-07-22 2011-01-27 Novartis Ag Arylpyrazoles and arylisoxazoles and their use as pkd modulators
AU2010319879A1 (en) 2009-10-29 2012-06-14 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds
WO2012052395A1 (en) 2010-10-18 2012-04-26 N. V. Organon Isoxazole derivatives used as oestrogen modulators
US8785435B2 (en) 2011-10-20 2014-07-22 Hoffmann-La Roche Inc. Solid forms
US8604062B2 (en) 2011-10-20 2013-12-10 Hoffman-La Roche Inc. Process for the preparation of isoxazolyl-methoxy nicotinic acids
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP2782584B1 (de) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natürliche kombinierte hormonersatzformulierungen und -therapien
KR102438072B1 (ko) * 2012-01-12 2022-08-31 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
MX2014009322A (es) 2012-02-29 2014-11-10 Repros Therapeutics Inc Terapia de combinacion para el tratamiento de la deficiencia androgenica.
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
HRP20181290T1 (hr) * 2013-11-05 2018-10-19 Bayer Cropscience Aktiengesellschaft Novi spojevi za suzbijanje člankonožaca
US20170266166A1 (en) * 2014-05-17 2017-09-21 University Of Rochester Compositions and Methods to Inhibit Estrogen Receptor Beta for the Treatment of Renal Cell Carcinoma
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US11633382B2 (en) 2015-11-10 2023-04-25 Paracrine Therapeutics Ab Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and anti-estrogen
WO2017107754A1 (zh) * 2015-12-22 2017-06-29 江苏恒瑞医药股份有限公司 苯并哌啶类衍生物、其制备方法及其在医药上的应用
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
GB201706806D0 (en) 2017-04-28 2017-06-14 Sentinel Oncology Ltd Pharmaceutical compounds
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
GB202015187D0 (en) 2020-09-25 2020-11-11 Sentinel Oncology Ltd A pharmaceutical salt
CN115710234B (zh) * 2022-11-02 2024-04-16 华南理工大学 一类具有抗肿瘤活性的3,4,5-三取代异噁唑类化合物及其制备方法和应用
KR102787749B1 (ko) * 2022-12-29 2025-03-31 중앙대학교 산학협력단 비스이소옥사졸 화합물을 유효성분으로 함유하는 퇴행성 뇌질환 예방 또는 치료용 조성물

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE295630C (de)
DE295360C (de)
FR2104932A1 (en) 1970-09-08 1972-04-28 Ferlux O-hydroxyphenyl pyrazoles - hypocholesterolemics anti inflammatories analgesics etc
DE2250343A1 (de) 1972-10-13 1974-04-18 Thiemann Chem Pharm Fab 4,6-disubstituierte resorcinverbindungen
ZA744908B (en) 1973-09-17 1975-08-27 American Cyanamid Co Catalytic dehydrogenation process for the preparation of 3,5-disubstituted pyrazoles
US4112108A (en) 1976-12-06 1978-09-05 Sandoz, Inc. Isoxazolyl benzamides
US4229204A (en) * 1978-12-04 1980-10-21 Monsanto Company Trifluoromethylphenyl isoxazolyl benzoates
JPS5583766A (en) 1978-12-18 1980-06-24 Sankyo Co Ltd Isoxazolin-3-one derivative
US4268678A (en) 1979-09-04 1981-05-19 Sterling Drug Inc. 4-(Arylaliphatic)isoxazoles
CA1128526A (en) 1979-10-05 1982-07-27 Cdc Life Sciences Inc. 3,4-diarylisoxazol-5-acetic acids
DE3119727A1 (de) 1981-05-18 1982-12-02 Sterling Drug Inc., 10019 New York, N.Y. "4-(arylaliphatische)-isoxazole, welche als antivirale mittel nuetzlich sind, und deren herstellung"
DD295630A5 (de) 1987-07-03 1991-11-07 Akad Wissenschaften Verfahren zur herstellung von beta-lactamantibiotika
DD295360A5 (de) 1987-07-03 1991-10-31 Akad Wissenschaften Verfahren zur Herstellung von aktivierten Carbonsäureestern
DE3832570A1 (de) 1988-09-24 1990-03-29 Hoechst Ag 7-substituierte derivate der 3,5-dihydroxyhept-6-insaeure, verfahren zur ihrer herstellung, ihre verwendung als arzneimittel, sowie zwischenprodukte
US5116839A (en) 1989-06-26 1992-05-26 Sankyo Company, Limited Use of isoxazolin-3-one derivatives as antidepressants
JP2786683B2 (ja) 1989-08-15 1998-08-13 三共株式会社 グリコール誘導体およびその用途
JO1645B1 (en) 1989-12-26 1991-11-27 شركة جانسين فارماسوتيكا ان. في Pyridazine compounds are antibacterial viruses
JPH03208044A (ja) 1990-01-10 1991-09-11 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
CA2036192A1 (en) 1990-02-13 1991-08-14 Nicholas Meanwell Heterocyclic carboxylic acids and esters
ATE108448T1 (de) 1990-05-11 1994-07-15 Sankyo Co Piperdinyloxy- und chinindidinyloxy- isoxazol- derivate, ihre herstellung und ihre therapeutische verwendung.
DE4126543A1 (de) 1991-08-10 1993-02-11 Chem & Pharm Patent Hold Ltd 3(5)-(hydroxyaryl)-pyrazole und ihre verwendung als wirkstoffe in arzneimittel
DE4129779A1 (de) * 1991-09-07 1993-03-11 Boehringer Mannheim Gmbh Neue tricyclische thiazol- und oxazol-derivate und diese enthaltende arzneimittel
DE4230839A1 (de) 1991-09-18 1993-03-25 Ciba Geigy Ag Polyarylenether mit pyrazoleinheiten
CA2099630A1 (en) 1992-07-02 1994-01-03 Guy Dominic Diana Heterocyclyl-phenoxyalkyl-piperidinylpyridazines as antiviral agents
JPH06135948A (ja) 1992-10-30 1994-05-17 Taiho Yakuhin Kogyo Kk スチレン誘導体又はその塩
TW240217B (de) 1992-12-30 1995-02-11 Glaxo Group Ltd
WO1994017059A1 (fr) 1993-01-29 1994-08-04 Nippon Soda Co., Ltd. Derive heterocyclique
WO1994018201A1 (fr) 1993-02-12 1994-08-18 Sankyo Company, Limited Derive d'isoxazoleoxy
IT1266582B1 (it) 1993-07-30 1997-01-09 Recordati Chem Pharm Derivati (di)azacicloesanici e diazacicloeptanici
WO1995006032A1 (fr) 1993-08-20 1995-03-02 Banyu Pharmaceutical Co., Ltd. Inhibiteur de la tyrosine kinase
IL111613A0 (en) 1993-11-12 1995-01-24 Rhone Poulenc Rorer Ltd Substituted phenyl compounds, their preparation and pharmaceutical compositions containing them
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
JPH07215952A (ja) 1993-12-06 1995-08-15 Otsuka Pharmaceut Factory Inc カテコール誘導体
US5547967A (en) 1993-12-08 1996-08-20 Kali-Chemie Pharma Gmbh (Phenylalkylaminoalkyloxy)-heteroaryl-compounds, processes and intermediates for their production and pharmaceutical compositions containing them
AU684887B2 (en) * 1994-03-09 1998-01-08 Pfizer Inc. Isoxazoline compounds as inhibitors of TNF release
DE4408084A1 (de) 1994-03-10 1995-09-14 Hoechst Ag 3,5-Disubstituierte und 3,4,5-trisubstituierte 2-Isoxazoline und Isoxazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5547975A (en) * 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
JP3267300B2 (ja) 1995-02-13 2002-03-18 ジー.ディー.サール アンド カンパニー 炎症の治療のための置換イソオキサゾール
JP3208044B2 (ja) 1995-06-07 2001-09-10 東京エレクトロン株式会社 プラズマ処理装置及びプラズマ処理方法
WO1997001551A1 (en) 1995-06-26 1997-01-16 Fujisawa Pharmaceutical Co., Ltd. Pyrazole compounds and pharmaceutical compositions
US5861359A (en) 1995-07-25 1999-01-19 Fmc Corporation Herbicidal phenylmethoxphenyl heterocycles
US6030970A (en) * 1995-08-02 2000-02-29 Smithkline Beecham Corporation Endothelin receptor antagonists
DE69628705T2 (de) 1995-08-24 2004-05-13 Basf Ag Isoxazole- und Isothiazole-5-carboxamid Derivate, deren Herstellung und deren Verwendung als Herbizide
US6020121A (en) 1995-09-29 2000-02-01 Microcide Pharmaceuticals, Inc. Inhibitors of regulatory pathways
JPH09291082A (ja) * 1996-02-27 1997-11-11 Sankyo Co Ltd イソキサゾール誘導体
AU2151897A (en) * 1996-03-15 1997-10-10 Aarhus Universitets Forskningsfond Bis-heterocyclic derivatives
AUPO044596A0 (en) * 1996-06-14 1996-07-11 Skop Gmbh Ltd Improved electrical signal supply
SI9720059B (sl) * 1996-08-14 2011-11-30 Searle & Co Kristalinična oblika 4-/5-metil-3-fenilizoksazol-4-il/benzensulfonamida
US6187797B1 (en) * 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
AU727654B2 (en) * 1997-06-13 2000-12-21 Yamanouchi Pharmaceutical Co., Ltd. Tricyclic pyrazole derivative
PT1054874E (pt) * 1998-02-13 2003-01-31 Upjohn Co Derivados de aminofenil-isoxazolina substituidos uteis como anti-microbianos
ID26804A (id) * 1998-04-08 2001-02-08 Lilly Co Eli Metode untuk menghambat mrp1
ATE315033T1 (de) * 1998-08-07 2006-02-15 Chiron Corp Subtituierte isoxazole derivate als estrogen rezeptor modulatore
EP1119568B1 (de) * 1998-10-09 2004-02-18 Janssen Pharmaceutica N.V. 4,5-dehydroisoxazole derivate und ihre pharmazeutische verwendung
CN1281604C (zh) 1999-06-03 2006-10-25 帝国脏器制药株式会社 取代吡唑化合物
DE19953024A1 (de) * 1999-11-04 2001-05-10 Merck Patent Gmbh Isoxazolderivate als Phosphodiesterase VII-Hemmer
BR0016086A (pt) * 1999-12-02 2002-08-06 Basf Ag Benzoilpirazol 3-(4,5-diidroisoxazol-3-il) substituìdo, processo para preparar benzoilpirazóis 3-(4,5-diidroisoxazol-3-il) substituìdos, composto, composição, processo para a preparação de composição, método para controlar vegetação indesejável, e, uso dos benzolpirazóis 3-(4,5-diidroisoxazol-3-il) - substituìdos da fórmula i e/ou de seus sais agricolamente úteis
US6579880B2 (en) * 2000-06-06 2003-06-17 Ortho-Mcneil Pharmaceutical, Inc. Isoxazoles and oxadiazoles as anti-inflammatory inhibitors of IL-8
DE60122176T2 (de) * 2000-09-15 2007-07-05 Vertex Pharmaceuticals Inc., Cambridge Isoxazole und ihre verwendung als erk-inhibitoren
US6624311B2 (en) * 2000-10-27 2003-09-23 Bristol-Myers Squibb Pharma Company Enantioselective enzymatic aminolysis of a racemic 2-isoxazolylacetate alkyl ester

Also Published As

Publication number Publication date
DE69929345D1 (de) 2006-03-30
EP1102755B1 (de) 2006-01-04
US6869969B2 (en) 2005-03-22
US6743815B2 (en) 2004-06-01
DE69929345T2 (de) 2006-09-21
EP1102755A1 (de) 2001-05-30
US6387920B2 (en) 2002-05-14
US20040102498A1 (en) 2004-05-27
JP2002522425A (ja) 2002-07-23
WO2000008001A1 (en) 2000-02-17
US6262098B1 (en) 2001-07-17
US20010036956A1 (en) 2001-11-01
AU5467699A (en) 2000-02-28
US20030065012A1 (en) 2003-04-03
ES2255294T3 (es) 2006-06-16

Similar Documents

Publication Publication Date Title
DE69929345D1 (de) Subtituierte isoxazole derivate als estrogen rezeptor modulatore
DE69935335D1 (de) Pyrazole als modulatoren des östrogenrezeptors
YU596A (sh) Estrogen agonisti/antagonisti
YU7797A (sh) Kombinovana terapija za osteoporozu
AU4926301A (en) Lpa receptor agonists and antagonists and methods of use
DE69914726D1 (de) Zusammensetzung zur regulierung des hauterscheinungsbildes
DE69930835D1 (de) Bicyclische pyridin-und pyrimidinderivate als neuropeptid y rezeptorantagonisten
TR200100267T2 (tr) İkameli anilid bileşimleri ve yöntemler.
TW427989B (en) Mesylate trihydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one
BR0006265A (pt) Composto de tetrahidroisoquinolinas como agonistas/antagonistas de estrogênios
NO20022655L (no) <Beta>-2-adrenerge reseptoragonister
ES2168650T3 (es) Compuestos y metodos moduladores de receptores de androgenos.
YU18400A (sh) Prostaglanidin agonisti i njihova primena za tretiranje koštanih poremećaja
BR0010215A (pt) Derivados de indolina como antagonistas de progesterona
BR9510486A (pt) Compostos moduladores de receptores de esteróide e métodos
AU9102198A (en) Indole-3-carbinol, diindolylmethane and substituted analogs as antiestrogens
DE60205776D1 (en) Indolinon-derivative als protein-kinasehemmer
AP9801269A0 (en) Prostaglandin agonists.
BG104930A (en) 2-phenyl-1-[2-(-aminoethoxy)-benzyl]-indole in combination with estrogens
WO2004054501A3 (en) Methods of usig and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
FR2783707B1 (fr) Composition de maquillage comprenant une poly-alpha-olefine
UA72948C2 (uk) Заміщені похідні фенілпіперазину, фармацевтична композиція та спосіб лікування афективних або неврологічних захворювань і розладів
GB2340751B (en) Pharmaceutical compositions
GB9712966D0 (en) Novel chalcones
MY133390A (en) Azabicyclic 5ht1 receptor ligands

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1102755

Country of ref document: EP

REN Ceased due to non-payment of the annual fee